CDK4 and breast cancer: The combination of neratinib with trastuzumab and fulvestrant was efficacious against HER2mut ER+ BC in the SUMMIT basket trial (23, 25, 99), after progression on CDK4/6is (100), and the fulvestrant+neratinib combination in ER+HER2mut was further supported by the mutHER trial (101).